Skip to content
Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase
Department of Family Medicine and Primary Care, Department of Medicine, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, School of Clinical Medicine, School of Nursing
Go to Link
Archive

Citation

Wan, E. Y. F., Wang, B., Mathur, S., Chan, C. I. Y., Yan, V. K. C., Lai, F. T. T., … Chan, E. W. Y. (2023, June). Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase. Journal of Infection. Elsevier BV. http://doi.org/10.1016/j.jinf.2023.02.029

Resource Type

ScholarlyArticle
#Infectious disease #Microbiology (medical)

Addition Details

Date:

2023-02-22

Wave of COVID:

5th

Category:

Research

Source URL:

http://dx.doi.org/10.1016/j.jinf.2023.02.029